FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023593813> ?p ?o ?g. }

• W2023593813 endingPage "1343" @default.
• W2023593813 startingPage "1343" @default.
• W2023593813 abstract "To investigate the activity and local and systemic safety of the topical carbonic anhydrase inhibitor, dorzolamide hydrochloride.Four-week, double-masked, randomized, placebo-controlled, parallel, three-center study.Referral centers.Forty-eight patients with bilateral open angle glaucoma or ocular hypertension and intraocular pressure (IOP) greater than 22 mm Hg entered the study. Two of 28 patients receiving dorzolamide and two of 20 patients receiving placebo were withdrawn due to adverse experiences.Dorzolamide (2%) or placebo to each eye three times daily for 4 weeks.Diurnal IOP curves; ophthalmologic evaluations including corneal ultrasound pachymetry and endothelial cell count; and systemic evaluations including vital signs, blood chemistries, complete blood cell counts, urinalysis, electrocardiogram, and drug and carbonic anhydrase activity levels in red blood cells.Mean IOP at morning trough (8 AM) decreased from 27.1 mm Hg at baseline to 23.5 mm Hg on day 29 with dorzolamide (-13.3%) compared with a decrease from 27.1 mm Hg to 26.4 mm Hg with placebo (-2.3%). Peak activity occurred 2 hours after administration, with IOP decreasing from 26.8 mm Hg at baseline to 21.8 mm Hg on day 29 with dorzolamide (-18.4%) vs 26.1 mm Hg to 25.5 (-2.4%) with placebo. Mean corneal thickness was slightly increased for the dorzolamide-treated group compared with the placebo-treated group (0.009 mm vs 0.001 mm, respectively, P < .05) and changes in endothelial cell counts were similar (-24 cells/mm2 vs -27 cells/mm2, respectively, P > .25). Mean carbonic anhydrase isoenzyme II activity in red blood cells decreased to 21% of baseline in dorzolamide-treated patients. There were no clinically significant differences in ocular or laboratory parameters between the dorzolamide and placebo groups.Dorzolamide demonstrated significant IOP lowering activity over 4 weeks. It was well tolerated and there were no clinically significant changes in ocular or systemic safety parameters." @default.
• W2023593813 created "2016-06-24" @default.
• W2023593813 creator A5008047316 @default.
• W2023593813 creator A5016364883 @default.
• W2023593813 creator A5020308050 @default.
• W2023593813 creator A5038348561 @default.
• W2023593813 creator A5046226041 @default.
• W2023593813 creator A5047479802 @default.
• W2023593813 creator A5049304841 @default.
• W2023593813 creator A5084876732 @default.
• W2023593813 creator A5089384577 @default.
• W2023593813 date "1993-10-01" @default.
• W2023593813 modified "2023-09-26" @default.
• W2023593813 title "Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor" @default.
• W2023593813 cites W102824874 @default.
• W2023593813 cites W1449256536 @default.
• W2023593813 cites W171078749 @default.
• W2023593813 cites W171151539 @default.
• W2023593813 cites W1971210347 @default.
• W2023593813 cites W1973868971 @default.
• W2023593813 cites W1974514289 @default.
• W2023593813 cites W1992855819 @default.
• W2023593813 cites W1996190152 @default.
• W2023593813 cites W2004519308 @default.
• W2023593813 cites W2004949350 @default.
• W2023593813 cites W2014664159 @default.
• W2023593813 cites W2022428162 @default.
• W2023593813 cites W2023461639 @default.
• W2023593813 cites W2035840247 @default.
• W2023593813 cites W2037595899 @default.
• W2023593813 cites W2038206243 @default.
• W2023593813 cites W2046953730 @default.
• W2023593813 cites W2051454453 @default.
• W2023593813 cites W2065744422 @default.
• W2023593813 cites W2066368129 @default.
• W2023593813 cites W2078428794 @default.
• W2023593813 cites W2114975414 @default.
• W2023593813 cites W2147761146 @default.
• W2023593813 cites W2165451228 @default.
• W2023593813 cites W2259372757 @default.
• W2023593813 cites W2282755710 @default.
• W2023593813 cites W2480784990 @default.
• W2023593813 doi "https://doi.org/10.1001/archopht.1993.01090100051026" @default.
• W2023593813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8216014" @default.
• W2023593813 hasPublicationYear "1993" @default.
• W2023593813 type Work @default.
• W2023593813 sameAs 2023593813 @default.
• W2023593813 citedByCount "128" @default.
• W2023593813 countsByYear W20235938132012 @default.
• W2023593813 countsByYear W20235938132014 @default.
• W2023593813 countsByYear W20235938132015 @default.
• W2023593813 countsByYear W20235938132016 @default.
• W2023593813 countsByYear W20235938132017 @default.
• W2023593813 countsByYear W20235938132018 @default.
• W2023593813 countsByYear W20235938132019 @default.
• W2023593813 countsByYear W20235938132020 @default.
• W2023593813 countsByYear W20235938132021 @default.
• W2023593813 countsByYear W20235938132022 @default.
• W2023593813 countsByYear W20235938132023 @default.
• W2023593813 crossrefType "journal-article" @default.
• W2023593813 hasAuthorship W2023593813A5008047316 @default.
• W2023593813 hasAuthorship W2023593813A5016364883 @default.
• W2023593813 hasAuthorship W2023593813A5020308050 @default.
• W2023593813 hasAuthorship W2023593813A5038348561 @default.
• W2023593813 hasAuthorship W2023593813A5046226041 @default.
• W2023593813 hasAuthorship W2023593813A5047479802 @default.
• W2023593813 hasAuthorship W2023593813A5049304841 @default.
• W2023593813 hasAuthorship W2023593813A5084876732 @default.
• W2023593813 hasAuthorship W2023593813A5089384577 @default.
• W2023593813 hasConcept C118487528 @default.
• W2023593813 hasConcept C142724271 @default.
• W2023593813 hasConcept C181199279 @default.
• W2023593813 hasConcept C185592680 @default.
• W2023593813 hasConcept C204787440 @default.
• W2023593813 hasConcept C27081682 @default.
• W2023593813 hasConcept C2775914622 @default.
• W2023593813 hasConcept C2776521421 @default.
• W2023593813 hasConcept C2776727336 @default.
• W2023593813 hasConcept C2778073030 @default.
• W2023593813 hasConcept C2778076468 @default.
• W2023593813 hasConcept C2778527774 @default.
• W2023593813 hasConcept C2781092963 @default.
• W2023593813 hasConcept C42219234 @default.
• W2023593813 hasConcept C55493867 @default.
• W2023593813 hasConcept C71924100 @default.
• W2023593813 hasConceptScore W2023593813C118487528 @default.
• W2023593813 hasConceptScore W2023593813C142724271 @default.
• W2023593813 hasConceptScore W2023593813C181199279 @default.
• W2023593813 hasConceptScore W2023593813C185592680 @default.
• W2023593813 hasConceptScore W2023593813C204787440 @default.
• W2023593813 hasConceptScore W2023593813C27081682 @default.
• W2023593813 hasConceptScore W2023593813C2775914622 @default.
• W2023593813 hasConceptScore W2023593813C2776521421 @default.
• W2023593813 hasConceptScore W2023593813C2776727336 @default.
• W2023593813 hasConceptScore W2023593813C2778073030 @default.
• W2023593813 hasConceptScore W2023593813C2778076468 @default.
• W2023593813 hasConceptScore W2023593813C2778527774 @default.
• W2023593813 hasConceptScore W2023593813C2781092963 @default.

• next